Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer
Fig 4
Isobologram analysis of combined treatment with the STAT5 inhibitor pimozide and enzalutamide.
Isobologram experiments were carried out with enzalutamide and pimozide as introduced by Loewe [36]. Results of dose-response experiments and graphical illustration of the combination index (CI) in C4-2 cells (A), MR49F cells (B), LAPC4-CTRL (C), and LAPC4-EnzaR cells (D). Cell viability after enzalutamide and pimozide treatment was assessed by MTT viability assays. Data is shown as mean±s.e.m. of three independent experiments.